Skip to Main Content

Patients with advanced kidney cancer live longer when treated with a combination of drugs from Bristol Myers Squibb and Exelixis compared to an older medicine, according to new clinical trial results reported Sunday.

Convincing physicians to prescribe the new combination regimen for kidney cancer patients, though, will face a challenge: equally effective treatments already in use.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED